Raymond James & Associates Boosts Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Raymond James & Associates boosted its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 212.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 394,006 shares of the company’s stock after buying an additional 267,951 shares during the quarter. Raymond James & Associates owned approximately 0.11% of GoodRx worth $2,734,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the business. Millennium Management LLC boosted its stake in GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after acquiring an additional 1,102,758 shares in the last quarter. Rubric Capital Management LP raised its holdings in GoodRx by 76.5% in the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after acquiring an additional 1,619,748 shares during the last quarter. American Century Companies Inc. purchased a new stake in GoodRx during the 2nd quarter valued at $18,183,000. Picton Mahoney Asset Management increased its holdings in shares of GoodRx by 24.3% in the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock worth $4,736,000 after purchasing an additional 118,703 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of GoodRx in the first quarter worth $1,638,000. 63.77% of the stock is owned by institutional investors.

GoodRx Price Performance

NASDAQ:GDRX opened at $5.87 on Tuesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32. The business has a 50 day simple moving average of $7.10 and a 200-day simple moving average of $7.55. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -45.15, a PEG ratio of 3.86 and a beta of 1.39. GoodRx Holdings, Inc. has a 1 year low of $4.14 and a 1 year high of $9.26.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. During the same period last year, the company earned $0.02 EPS. The business’s revenue was up 5.7% compared to the same quarter last year. Equities analysts forecast that GoodRx Holdings, Inc. will post 0.14 EPS for the current year.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. UBS Group cut their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research note on Friday, August 9th. Citigroup lowered their price objective on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GoodRx currently has a consensus rating of “Moderate Buy” and an average target price of $9.36.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.